HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kaiser, C. I. Articles by Kaser-Hotz, B. Search for Related Content PubMed PubMed Citation Articles by Kaiser, C. I. Articles by Kaser-Hotz, B.

Reevaluation of the University of Wisconsin 2-Year Protocol for Treating Canine Lymphosarcoma

From the Department of Veterinary Clinical Sciences (Fidel), Washington State University, Pullman, Washington 99164-6610; the Department of Biostatistics (Roos), ISPM, University of Zurich, Sumatrastrasse 30, CH-8006, Zurich, Switzerland; and the Department of Diagnostic Imaging and Radiation Oncology (Kaiser, Kaser-Hotz), Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, CH-8057, Zurich, Switzerland.

Address all correspondence to Dr. Fidel.

This retrospective study investigated a population of 96 dogs with newly diagnosed malignant lymphosarcoma that were treated with the commonly used University of Wisconsin-Madison (UW-M) chemotherapy protocol. Pretreatment characteristics were analyzed to determine prognostic factors. Dogs with higher World Health Organization (WHO) stages (including stage IV) and dogs with hypercalcemia were at significantly higher risk of relapse (P=0.018 and P=0.016, respectively). Dose reduction, treatment delays, and prior therapy with cortico-steroids were not associated with clinical outcome. First remission duration of 270 days was similar to historically reported data. Overall survival time of 218 days was much shorter than historical data.